Company: CERO
Filing Date: 2025-07-02
Form Type: 424B3
Source: 0001213900-25-061023
Chunk: 1

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-02
Form: 424B3
Chunk 1
---
 risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in “Risk Factors” beginning on page 8 of the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or determined if the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this Prospectus Supplement is July 2, 2025.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25, 2025

CERO THERAPEUTICS HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)</div>

| Delaware                                       |     | 001-40877               |     | 81-4182129         |
| (State or Other Jurisdiction of Incorporation) |     | -Commission File Number |     | -IRS Employer      
 Identification No. |

| 201 Haskins Way, Suite 230               |     |           |
| South San Francisco, California          |     |     94080 |
| (Address of Principal Executive Offices) |     | -Zip Code |

<div align='center'>Registrant’s Telephone Number, Including Area Code: 650-407-2376

(Former Name or Former Address, if Changed Since Last Report)</div>

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ☐ | Written communications pursuant to Rule 425 under the Securities 
 Act (17 CFR 230.425)                                             |

| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange 
 Act (17 CFR 240.14a-12)                                        |

| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under 
 the Exchange Act (17 CFR 240.14d-2(b))                          |

| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under 
 the Exchange Act (17 CFR 240.13e-4(c))                          |

<div align='center'>Securities